BlackRock’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-19,109
| Closed | -$95.6K | – | 5428 |
|
|
2024
Q1 | $95.6K | Sell |
19,109
-349
| -2% | -$2.17K | ﹤0.01% | 4740 |
|
|
2023
Q4 | $131K | Sell |
19,458
-10,080
| -34% | -$88.6K | ﹤0.01% | 4744 |
|
|
2023
Q3 | $270K | Sell |
29,538
-1,700
| -5% | -$34.2K | ﹤0.01% | 4591 |
|
|
2023
Q2 | $660K | Sell |
31,238
-62,330
| -67% | -$1.92M | ﹤0.01% | 4407 |
|
|
2023
Q1 | $2.52M | Sell |
93,568
-1,622
| -2% | -$75.4K | ﹤0.01% | 3942 |
|
|
2022
Q4 | $3.37M | Buy |
95,190
+4,001
| +4% | +$481K | ﹤0.01% | 3904 |
|
|
2022
Q3 | $20.6M | Sell |
91,189
-702
| -0.8% | -$173K | ﹤0.01% | 3013 |
|
|
2022
Q2 | $17.4M | Buy |
91,891
+10,416
| +13% | +$2.1M | ﹤0.01% | 3156 |
|
|
2022
Q1 | $20.3M | Sell |
81,475
-957
| -1% | -$151K | ﹤0.01% | 3168 |
|
|
2021
Q4 | $12.8M | Sell |
82,432
-39
| -0% | -$7.54K | ﹤0.01% | 3523 |
|
|
2021
Q3 | $16.5M | Sell |
82,471
-66
| -0.1% | -$15.7K | ﹤0.01% | 3411 |
|
|
2021
Q2 | $21.1M | Sell |
82,537
-1,161
| -1% | -$290K | ﹤0.01% | 3262 |
|
|
2021
Q1 | $22.2M | Buy |
83,698
+4,522
| +6% | +$1.42M | ﹤0.01% | 3130 |
|
|
2020
Q4 | $29.2M | Buy |
79,176
+4,303
| +6% | +$1.23M | ﹤0.01% | 2809 |
|
|
2020
Q3 | $18.3M | Buy |
74,873
+9,287
| +14% | +$2.89M | ﹤0.01% | 2904 |
|
|
2020
Q2 | $18.9M | Buy |
65,586
+3,446
| +6% | +$1.02M | ﹤0.01% | 2825 |
|
|
2020
Q1 | $12.7M | Sell |
62,140
-850
| -1% | -$271K | ﹤0.01% | 2866 |
|
|
2019
Q4 | $28.2M | Buy |
62,990
+3,603
| +6% | +$1.28M | ﹤0.01% | 2691 |
|
|
2019
Q3 | $18.3M | Buy |
59,387
+1,748
| +3% | +$568K | ﹤0.01% | 2863 |
|
|
2019
Q2 | $18.3M | Buy |
57,639
+42,547
| +282% | +$14.7M | ﹤0.01% | 2889 |
|
|
2019
Q1 | $6.33M | Sell |
15,092
-531
| -3% | -$213K | ﹤0.01% | 3329 |
|
|
2018
Q4 | $4.76M | Buy |
15,623
+8,135
| +109% | +$2.63M | ﹤0.01% | 3407 |
|
|
2018
Q3 | $2.69M | Buy |
7,488
+179
| +2% | +$61.2K | ﹤0.01% | 3674 |
|
|
2018
Q2 | $2.67M | Buy |
7,309
+4,612
| +171% | +$1.64M | ﹤0.01% | 3638 |
|
|
2018
Q1 | $797K | Buy |
2,697
+1,737
| +181% | +$513K | ﹤0.01% | 3940 |
|
|
2017
Q4 | $402K | Buy |
960
+24
| +3% | +$8.57K | ﹤0.01% | 4087 |
|
|
2017
Q3 | $310K | Sell |
936
-22
| -2% | -$5.99K | ﹤0.01% | 4144 |
|
|
2017
Q2 | $226K | Sell |
958
-5,230
| -85% | -$1.19M | ﹤0.01% | 4226 |
|
|
2017
Q1 | $2.13M | Buy |
6,188
+6,183
| +123,660% | +$2.13M | ﹤0.01% | 3636 |
|
|
2016
Q4 | $2K | Hold |
5
| – | – | ﹤0.01% | 3659 |
|
|
2016
Q3 | $2K | Hold |
5
| – | – | ﹤0.01% | 3626 |
|
|
2016
Q2 | $3K | Buy |
+5
| New | +$3.04K | ﹤0.01% | 3608 |
|
Other funds holding EIGR
BlackRock's EIGR Position: Q2 2024 in Review
BlackRock sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2024, closing a stake of 19,109 shares — an estimated $95.6K sold.
BlackRock first reported a position in EIGR in Q2 2016 and held it in 32 quarters. The position peaked at $29.2M in Q4 2020. 2 funds tracked by Wall St. Rank hold EIGR as of Q2 2024.
- BlackRock reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- BlackRock sold 19,109 Eiger BioPharmaceuticals, Inc. shares in Q2 2024, an estimated $95.6K.
- BlackRock first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2016 and held it in 32 quarters.
- BlackRock's Eiger BioPharmaceuticals, Inc. position peaked at $29.2M in Q4 2020.
- 2 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2024.
Based on BlackRock's 13F filing for Q2 2024, filed 13 Aug 2024.